As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …

The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of
Alzheimer's disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for …

Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …

Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration
could identify individuals at risk for cognitive decline in Alzheimer's disease (AD). In blood …

Abstract Alzheimer's disease (AD), the most common form of dementia, remains challenging
to understand and treat despite decades of research and clinical investigation. This might be …

Skeletal muscle atrophy is prevalent in a myriad of pathological conditions, such as
diabetes, denervation, long-term immobility, malnutrition, sarcopenia, obesity, Alzheimer's …

Biomarker testing is recommended for the accurate and timely diagnosis of Alzheimer's
disease (AD). Using illustrative case narratives we consider how cerebrospinal fluid (CSF) …

Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations
with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p …

Age-associated cerebral small vessel disease (CSVD) represents a clinically heterogenous
condition, arising from diverse microvascular mechanisms. These lead to chronic …

Biomarkers that predict the clinical onset of Alzheimer's disease (AD) enable the
identification of individuals in the early, preclinical stages of the disease. Detecting AD at this …